Preclinical study shows promise of systemic targeted therapy in a rare form of cancer

Treatment with BRAF inhibitors reduces tumor cell proliferation in subcutaneous BRAFV600E PMP-PDX tumors without impacting in apoptosis. a–d) Mice bearing subcutaneous BRAF mutant PMP-PDX tumors (PMP5.1) were treated with vehicle, cetuximab, encorafenib or doublet. Credit: Clinical Cancer Research (2024). DOI: 10.1158/1078-0432.CCR-23-4072 Pseudomyxoma peritonei is a rare and poorly understood cancer, characterized by the progressive accumulation of mucin in the abdominal cavity. Mainstay treatments are surgery and chemotherapy but disease recurrence and death after relapse frequently occur. The development of new, more effective therapeutic strategies represents an unmet clinical need. Results of a preclinical study, published in Clinical Cancer Research, led Read More